Trials / Not Yet Recruiting
Not Yet RecruitingNCT06963398
A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
A Phase 1 Study, Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10529 Monotherapy in KRAS G12D Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 520 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.
Detailed description
This is a phase 1, first-in-human, study of HS-10529, consisting of dose escalation and dose expansion, which is aimed to assess the safety and tolerability of HS-10529 in KRAS G12D patients with advanced solid tumors and evaluate the preliminary efficacy of HS-10529.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10529 | Participants in all subjucts will receive HS-10529 |
Timeline
- Start date
- 2025-05-15
- Primary completion
- 2029-04-30
- Completion
- 2029-08-30
- First posted
- 2025-05-09
- Last updated
- 2025-05-09
Source: ClinicalTrials.gov record NCT06963398. Inclusion in this directory is not an endorsement.